OtherBASIC SCIENCE INVESTIGATIONS

PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)–Conjugated Radiolabeled Iron Oxide Nanoparticles

Ha-Young Lee, Zibo Li, Kai Chen, Andrew R. Hsu, Chenjie Xu, Jin Xie, Shouheng Sun and Xiaoyuan Chen
Journal of Nuclear Medicine August 2008, 49 (8) 1371-1379; DOI: https://doi.org/10.2967/jnumed.108.051243

Article Figures & Data

Figures

  • FIGURE 1. 
    FIGURE 1. 

    (A) Synthesis of PET/MRI dual functional probe DOTA-IO-RGD. DOTA-IO was prepared similarly except that no RGD peptide was used. (B) Illustration of PET/MRI probe based on IO nanoparticle.

  • FIGURE 2. 
    FIGURE 2. 

    (A) TEM image of PASP-coated IO nanoparticle. (B) Selected-area electron diffraction pattern of PASP-coated IO nanoparticle. (C) High-resolution TEM image of PASP-coated IO nanoparticle. (D) Magnetization curve of PASP-coated IO nanoparticle.

  • FIGURE 3. 
    FIGURE 3. 

    (A) Phantom image acquired from T1-weighted MRI scan (top) and T2-weighted MRI scan (bottom) for ferumoxide and PASP-IO at different iron concentrations. (B) 1/T2 (top) and 1/T2* (bottom) vs. Fe concentration for PASP-IO and ferumoxide. Relaxivity values r2 and r2* were obtained from slopes of linear fits of experimental data.

  • FIGURE 4. 
    FIGURE 4. 

    Inhibition of 125I-echistatin (integrin αvβ3–specific) binding to integrin αvβ3 on U87MG cells by DOTA-IO-RGD, c(RGDyK), and DOTA-IO (n = 3, mean ± SD).

  • FIGURE 5. 
    FIGURE 5. 

    (A) Decay-corrected whole-body coronal PET images of nude mouse bearing human U87MG tumor at 1, 4, and 21 h after injection of 3.7 MBq of 64Cu-DOTA-IO, 64Cu-DOTA-IO-RGD, or 64Cu-DOTA-IO-RGD with 10 mg of c(RGDyK) peptide per kilogram (300 μg of iron-equivalent IO particles per mouse). (B) Time–activity curves of U87MG tumors after injection of 3.7 MBq of 64Cu-DOTA-IO, 64Cu-DOTA-IO-RGD, or 64Cu-DOTA-IO-RGD with blocking dose of c(RGDyK) (n = 3/group).

  • FIGURE 6. 
    FIGURE 6. 

    T2-weighted MR images of nude mice bearing U87MG tumor before injection of IO nanoparticles (A and E) and at 4 h after tail-vein injection of DOTA-IO (B and F), DOTA-IO-RGD (C and G), and DOTA-IO-RGD with blocking dose of c(RGDyK) (D and H).

  • FIGURE 7. 
    FIGURE 7. 

    Prussian blue–stained U87MG tumor, liver, and spleen sections after injection of 64Cu-DOTA-IO-RGD, 64Cu-DOTA-IO, and 64Cu-DOTA-IO-RGD with blocking dose of c(RGDyK). IO was stained as blue spots in figure (magnification, 200×).

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section